Gantenerumab for Early Alzheimer's Disease: An Updated Systematic Review and Meta-Analysis. | ClinicLens
Alzheimer's disease (AD) is a progressive neurodegenerative disorder with limited treatment options. Gantenerumab, a β-amyloid-targeting monoclonal antibody, has shown mixed clinical results. With new trial data available, this updated systematic review and meta-analysis re-
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.